These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30188773)

  • 41. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma.
    Erkin EF; Tarhan S; Kayikçioğlu OR; Deveci H; Güler C; Göktan C
    Eur J Ophthalmol; 2004; 14(3):211-9. PubMed ID: 15206646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients.
    Gao LC; Wang D; Liu FQ; Huang ZY; Huang HG; Wang GH; Chen X; Shi QZ; Hong L; Wu LP; Tang J
    Eur J Clin Pharmacol; 2015 Jan; 71(1):43-50. PubMed ID: 25339146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Four years later: a clinical update on latanoprost.
    Ravinet E; Mermoud A; Brignoli R
    Eur J Ophthalmol; 2003 Mar; 13(2):162-75. PubMed ID: 12696636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PTGFR and SLCO2A1 Gene Polymorphisms Determine Intraocular Pressure Response to Latanoprost in Han Chinese Patients with Glaucoma.
    Zhang P; Jiang B; Xie L; Huang W
    Curr Eye Res; 2016 Dec; 41(12):1561-1565. PubMed ID: 27336732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
    Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA;
    Eur J Ophthalmol; 2005; 15(5):562-80. PubMed ID: 16167287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
    Martinez A; Sanchez M
    Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.
    Iskedjian M; Walker JH; Desjardins O; Robin AL; Covert DW; Bergamini MV; Einarson TR
    Curr Med Res Opin; 2009 Aug; 25(8):1879-88. PubMed ID: 19530975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.
    Garway-Heath DF; Crabb DP; Bunce C; Lascaratos G; Amalfitano F; Anand N; Azuara-Blanco A; Bourne RR; Broadway DC; Cunliffe IA; Diamond JP; Fraser SG; Ho TA; Martin KR; McNaught AI; Negi A; Patel K; Russell RA; Shah A; Spry PG; Suzuki K; White ET; Wormald RP; Xing W; Zeyen TG
    Lancet; 2015 Apr; 385(9975):1295-304. PubMed ID: 25533656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial.
    Mansouri K; Orguel S; Mermoud A; Haefliger I; Flammer J; Ravinet E; Shaarawy T
    Br J Ophthalmol; 2008 Mar; 92(3):332-6. PubMed ID: 18211927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma.
    Oh JY; Park KH
    Korean J Ophthalmol; 2005 Dec; 19(4):297-301. PubMed ID: 16491821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of latanoprost as adjunctive therapy.
    DesMarchais B; Candal E; Weitzman M; Shields MB
    Can J Ophthalmol; 2000 Jun; 35(4):214-7. PubMed ID: 10900518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis.
    Webers CA; Beckers HJ; Zeegers MP; Nuijts RM; Hendrikse F; Schouten JS
    Ophthalmology; 2010 Nov; 117(11):2067-74.e1-6. PubMed ID: 20619459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy.
    Diestelhorst M; Nordmann JP; Toris CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S155-61. PubMed ID: 12204713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
    Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
    J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
    Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
    Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.